Adma Biologics Inc (NASDAQ:ADMA) has a beta value of 0.60 and has seen 0.41 million shares traded in the recent trading session. The company, currently valued at $4.26B, closed the recent trade at $18.04 per share which meant it gained $0.69 on the day or 3.98% during that session. The ADMA stock price is -31.04% off its 52-week high price of $23.64 and 67.41% above the 52-week low of $5.88. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.28 million shares traded. The 3-month trading volume is 2.45 million shares.
The consensus among analysts is that Adma Biologics Inc (ADMA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.14.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Sporting 3.98% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ADMA stock price touched $18.04 or saw a rise of 1.96%. Year-to-date, Adma Biologics Inc shares have moved 5.19%, while the 5-day performance has seen it change 2.04%. Over the past 30 days, the shares of Adma Biologics Inc (NASDAQ:ADMA) have changed 8.28%. Short interest in the company has seen 14.23 million shares shorted with days to cover at 6.64.
Wall Street analysts have a consensus price target for the stock at $18, which means that the shares’ value could drop -0.22% from the levels at last check today. The projected low price target is $18.0 while the price target rests at a high of $18.0. In that case, then, we find that the latest price level in today’s session is 0.22% off the targeted high while a plunge would see the stock lose 0.22% from the levels at last check today.
Adma Biologics Inc (ADMA) estimates and forecasts
The company’s shares have lost -1.85% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 15.59%.
2 analysts offering their estimates for the company have set an average revenue estimate of 115.5M for the current quarter. 2 have an estimated revenue figure of 120.7M for the next ending quarter. Year-ago sales stood 81.88M and 107.19M respectively for this quarter and the next, and analysts expect sales will grow by 41.07% for the current quarter and 15.59% for the next.
Earnings growth for 2025 is a modest 43.56% while over the next 5 years, the company’s earnings are expected to increase by 31.08%.
ADMA Dividends
Adma Biologics Inc is expected to release its next earnings report on 2025-Mar-02 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders own 2.66% of the company shares, while shares held by institutions stand at 88.66% with a share float percentage of 91.09%. Investors are also buoyed by the number of investors in a company, with Adma Biologics Inc having a total of 433.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 18.64 million shares worth more than $208.45 million. As of 2024-06-30, BLACKROCK INC. held 8.1462% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 14.52 million shares as of 2024-06-30. The firm’s total holdings are worth over $162.3 million and represent 6.3426% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 6.46% shares in the company for having 15.26 shares of worth $276.25 million while later fund manager owns 7.0 shares of worth $126.73 million as of Dec 31, 2024, which makes it owner of about 2.96% of company’s outstanding stock.
